Zydus Cadila receives USFDA tentative approval

Zydus Cadila announced that the pharma company has received a tentative approval from US Food & Drug Administration (USFDA) to market Carbidopa and Levodopa extended-release capsules in the strengths of 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg and 61.25 mg/245 mg.

Carbidopa and Levodopa extended-release capsules in the strengths of 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg and 61.25 mg/245 mg is a combination of medicines, indicated for the use or treatment of Parkinson’s disease or when having symptoms similar to Parkinson such as shakiness, stiffness and difficulty in moving. The medication is expected to be manufactured at the company’s facility located in SEZ, Ahmedabad.

Zydus Cadila is an innovative, global pharmaceutical company engaged in the discovery, development, manufacturing and marketing of a broad range of healthcare therapies. The group employs nearly 25,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020. The group currently has 282 approvals and has so far, filed over 386 ANDAs since the commencement of the filing process in FY 2003-2004.

On Monday, the stock of the company closed at Rs 252.10, down by 0.28 per cent or Rs 0.70 per share. The 52-week high is Rs 352.30 and 52-week low is Rs 206.45 on BSE.